Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards consisting of Restricted Stock Units (RSUs) representing 15,750 shares of common stock to two new non-executive employees. The awards, approved by the company's Compensation Committee under NASDAQ Listing Rule 5635(c)(4), serve as material inducements for employment. These RSUs will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, contingent on continued employment. The awards are governed by the Neuronetics 2020 Inducement Plan.
Neuronetics (NASDAQ: STIM) ha annunciato l'assegnazione di premi di inducimento costituiti da Restricted Stock Units (RSU) che rappresentano 15.750 azioni ordinarie a due nuovi dipendenti non esecutivi. I premi, approvati dal Comitato per la Retribuzione dell'azienda ai sensi della Regola di Quotazione NASDAQ 5635(c)(4), fungono da incentivi materiali per l'impiego. Queste RSU saranno acquisite in rate uguali nel corso di tre anni, nelle date del primo, secondo e terzo anniversario della data di concessione, a condizione di un impiego continuativo. I premi sono regolati dal Piano di Inducimento Neuronetics 2020.
Neuronetics (NASDAQ: STIM) ha anunciado la concesión de premios de inducimiento que consisten en Unidades de Acciones Restringidas (RSU) que representan 15.750 acciones ordinarias a dos nuevos empleados no ejecutivos. Los premios, aprobados por el Comité de Compensación de la compañía bajo la Regla de Cotización NASDAQ 5635(c)(4), sirven como incentivos materiales para el empleo. Estas RSU se consolidarán en cuotas iguales durante tres años en el primer, segundo y tercer aniversario de la fecha de concesión, sujeto a empleo continuado. Los premios están regidos por el Plan de Inducimiento Neuronetics 2020.
Neuronetics (NASDAQ: STIM)는 비이사 직원 두 명에게 15,750주 분의 보통주를 나타내는 제한 주식 단위(RSU)로 구성된 유도 보상을 부여했다고 발표했습니다. 이 보상은 NASDAQ 상장 규칙 5635(c)(4)에 따라 회사 보상 위원회에서 승인되었으며, 고용에 대한 중요한 유인으로 작용합니다. 이 RSU는 부여일의 첫 번째, 두 번째, 세 번째 기념일에 대한 동등한 할부로 3년에 걸쳐 분할됩니다. 이 보상은 지속적인 고용을 조건으로 합니다. 보상은 Neuronetics 2020 유도 플랜에 의해 관리됩니다.
Neuronetics (NASDAQ: STIM) a annoncé l'octroi de primes d'incitation sous forme d'Unités d'Actions Restreintes (RSU) représentant 15 750 actions ordinaires à deux nouveaux employés non exécutifs. Les primes, approuvées par le Comité de Rémunération de l'entreprise conformément à la Règle de Cotation NASDAQ 5635(c)(4), servent d'incitations matérielles à l'embauche. Ces RSU acquerront leurs droits par tranches égales sur une période de trois ans, aux premier, deuxième et troisième anniversaires de la date d'octroi, sous réserve d'un emploi continu. Les primes sont régies par le Plan d'Incitation Neuronetics 2020.
Neuronetics (NASDAQ: STIM) hat die Vergabe von Anreizprämien in Form von Restricted Stock Units (RSUs) bekannt gegeben, die 15.750 Stammaktien an zwei neue nicht-executive Mitarbeiter repräsentieren. Die Prämien wurden vom Vergütungsausschuss des Unternehmens gemäß der NASDAQ-Listing-Regel 5635(c)(4) genehmigt und dienen als materielle Anreize für die Beschäftigung. Diese RSUs werden in gleichen Raten über einen Zeitraum von drei Jahren am ersten, zweiten und dritten Jahrestag des Vergabedatums erworben, abhängig von der fortgesetzten Beschäftigung. Die Prämien unterliegen dem Neuronetics 2020 Anreizplan.
- Successful attraction of new talent through equity compensation
- Potential future dilution of existing shareholders from RSU issuance
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 15,750 shares of the Company’s common stock (RSUs) to two new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.
Each of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date. The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
About Neuronetics and Greenbrook
Neuronetics, Inc. (“Neuronetics”) believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations by offering exceptional treatments that produce extraordinary results. Neuronetics’ NeuroStar Advanced Therapy for Mental Health is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar system and associated treatment sessions to customers, Greenbrook TMS Inc. (“Greenbrook”) operates treatment centers across the United States, offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or “TMS”) and Spravato® (esketamine nasal spray) for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Spravato® is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. Greenbrook has provided more than 1.68 million treatments to over 51,000 patients struggling with depression.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
How many shares of STIM stock were granted as RSUs in February 2024?
What is the vesting schedule for STIM's February 2024 RSU grants?
Under which plan were STIM's February 2024 RSU inducement grants issued?
What is the purpose of STIM's February 2024 RSU grants?
